Abstract: The disclosure relates to a quantum dot structure. The quantum dot structure includes a quantum dot and a cloud-like shell covering a portion of the quantum dot and having an irregular outer surface. The quantum dot includes: a core; a first shell discontinuously around a core surface of the core; and a second shell between the core and the first shell and encapsulating the core surface of the core, wherein the second shell has an irregular outer surface.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: A wearable device can include a first sensor configured to sense first data, a second sensor configured to sense second data, an energy utilization of the first sensor being less than an energy utilization of the second sensor, and a processor configured to perform a comparison between the first data and a threshold value, if the comparison passes the threshold value, cause the second sensor to sense the second data and process the second data, and if the comparison fails the threshold value, cause the second sensor not to sense the second data.

Abstract: The present invention discloses a battery module and a power arrangement method. The battery module includes a battery unit, an energy storage element, a switch, a functional circuit and a control unit. The energy storage element is coupled to the battery unit. The switch is coupled to the energy storage element. The functional circuit is respectively coupled to the battery unit and the energy storage element. The control unit is respectively coupled to the functional circuit and the switch, configured to control the functional circuit to cause the energy storage element to be coupled to the battery unit so that the battery unit charges the energy storage unit, or configured to control the functional circuit to cause the energy storage element to be decoupled with the battery unit so that a discharge path is formed.

Abstract: A device (100) includes a display (110) itself including pixel groups. A bottom and sides of each of the pixel groups are covered with non-reflective material. The pixel groups are electrically coupled together with transparent conductive interconnections. A camera (122) is located beneath the display and the camera is configured to sense light that passes through the display.

Abstract: The present disclosure provides a test strip for milk immunofluorescence assay (IFA) and use thereof, and relates to the technical field of test strip. The test strip of the present disclosure includes a sample pad, a conjugate pad, a nitrocellulose membrane, and a wicking pad assembled and pasted successively on a PVC backing card; fluorescent latex microsphere-labeled mixed antibodies are coated on the conjugate pad; anti-casein antibody (T1 line), anti-beta-lactoglobulin (BLG) antibody (T2 line), anti-alpha-lactalbumin (ALA) antibody (T3 line), anti-lactoferrin/anti-bovine serum albumin (BSA) antibody (T4 line), and rabbit anti-mouse IgG antibody (C line) are coated on the nitrocellulose membrane, where the T1, T2, T3, and T4 lines are test lines, and the C line is a control line. The test strip of the present disclosure accurately and quantitatively detects the content of casein, BLG, ALA, and lactoferrin/BSA in food, and features easy operation and high accuracy and sensitivity.

Abstract: An apparatus includes a camera, a primary display panel including a pixel array and an aperture adjacent the pixel array, an auxiliary display, and an optical assembly including a reflecting optical element and an actuator coupled to the reflecting optical element. The actuator is configured to switch the reflecting optical element between a first arrangement and a second arrangement. The first arrangement defines an optical path from the aperture to the camera and the second arrangement defines an optical path from the aperture to the auxiliary display.

Abstract: The present invention discloses a battery module and a power arrangement method. The battery module includes a battery unit, an energy storage element, a switch, a functional circuit and a control unit. The energy storage element is coupled to the battery unit. The switch is coupled to the energy storage element. The functional circuit is respectively coupled to the battery unit and the energy storage element. The control unit is respectively coupled to the functional circuit and the switch, configured to control the functional circuit to cause the energy storage element to be coupled to the battery unit so that the battery unit charges the energy storage unit, or configured to control the functional circuit to cause the energy storage element to be decoupled with the battery unit so that a discharge path is formed.

Abstract: A device (100) includes a display (110) itself including pixel groups. A bottom and sides of each of the pixel groups are covered with non-reflective material. The pixel groups are electrically coupled together with transparent conductive interconnections. A camera (122) is located beneath the display and the camera is configured to sense light that passes through the display.

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.

Abstract: The present disclosure provides a test strip for peanut immunofluorescence assay (IFA), use thereof and a detection method, and relates to the technical field of IFA. The test strip of the present disclosure includes a sample pad, a conjugate pad, a nitrocellulose membrane, and a wicking pad arranged successively on a PVC backing card in a left-to-right and end-to-end manner; fluorescent latex microsphere-labeled mixed antibodies are coated on the conjugate pad; anti-Ara h 1 antibody (T1 line), anti-Ara h 2 antibody (T2 line), anti-Ara h 3 antibody (T3 line), anti-total peanut protein (TPP) antibodies (T4 line), and rabbit anti-mouse IgG antibody (C line) are coated on the nitrocellulose membrane, where the T1, T2, T3, and T4 lines are test lines, and the C line is a control line.

Abstract: The present disclosure provides a test strip for milk immunofluorescence assay (IFA) and use thereof, and relates to the technical field of test strip. The test strip of the present disclosure includes a sample pad, a conjugate pad, a nitrocellulose membrane, and a wicking pad assembled and pasted successively on a PVC backing card; fluorescent latex microsphere-labeled mixed antibodies are coated on the conjugate pad; anti-casein antibody (T1 line), anti-beta-lactoglobulin (BLG) antibody (T2 line), anti-alpha-lactalbumin (ALA) antibody (T3 line), anti-lactoferrin/anti-bovine serum albumin (BSA) antibody (T4 line), and rabbit anti-mouse IgG antibody (C line) are coated on the nitrocellulose membrane, where the T1, T2, T3, and T4 lines are test lines, and the C line is a control line. The test strip of the present disclosure accurately and quantitatively detects the content of casein, BLG, ALA, and lactoferrin/BSA in food, and features easy operation and high accuracy and sensitivity.

Abstract: An example method includes receiving, by a mobile computing device, electrical power via a wireless charging link between the mobile computing device and a wireless charging device; and responsive to an activation state of a camera of the mobile computing device, selectively adjusting, by the mobile computing device, one or more parameters of the wireless charging link, wherein wireless charging via the wireless charging link with the adjusted one or more parameters generates less noise in images captured by the camera while the mobile computing device receives electrical power via the wireless charging link than wireless charging with unadjusted one or more parameters.

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: An apparatus includes a camera, a primary display panel including a pixel array and an aperture adjacent the pixel array, an auxiliary display, and an optical assembly including a reflecting optical element and an actuator coupled to the reflecting optical element. The actuator is configured to switch the reflecting optical element between a first arrangement and a second arrangement. The first arrangement defines an optical path from the aperture to the camera and the second arrangement defines an optical path from the aperture to the auxiliary display.

Abstract: An example method includes receiving, by a mobile computing device, electrical power via a wireless charging link between the mobile computing device and a wireless charging device; and responsive to an activation state of a camera of the mobile computing device, selectively adjusting, by the mobile computing device, one or more parameters of the wireless charging link, wherein wireless charging via the wireless charging link with the adjusted one or more parameters generates less noise in images captured by the camera while the mobile computing device receives electrical power via the wireless charging link than wireless charging with unadjusted one or more parameters.

Abstract: An apparatus includes a camera, a primary display panel including a pixel array and an aperture adjacent the pixel array, an auxiliary display, and an optical assembly including a reflecting optical element and an actuator coupled to the reflecting optical element. The actuator is configured to switch the reflecting optical element between a first arrangement and a second arrangement. The first arrangement defines an optical path from the aperture to the camera and the second arrangement defines an optical path from the aperture to the auxiliary display.

Abstract: An apparatus includes a camera, a primary display panel including a pixel array and an aperture adjacent the pixel array, an auxiliary display, and an optical assembly including a reflecting optical element and an actuator coupled to the reflecting optical element. The actuator is configured to switch the reflecting optical element between a first arrangement and a second arrangement. The first arrangement defines an optical path from the aperture to the camera and the second arrangement defines an optical path from the aperture to the auxiliary display.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.